This information is for people in the UK and Republic of Ireland who are prescribed Dupixent® (dupilumab).

You are viewing information about

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly:

In the UK, via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.
In Ireland, at www.hpra.ie; email: medsafety@hpra.ie

Alternatively, you can report side effects to Sanofi on:

UK: Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com
IE: Tel: 01 403 5600 or send via email to IEPharmacovigilance@sanofi.com

By reporting side effects, you can help provide more information on the safety of this medicine.

Health information contained herein is provided for general educational purposes only. Please consult your healthcare professional if you have any questions about your health or treatment

The contents of this website have been developed and funded by Sanofi and Regeneron

MAT-XU-2303364 (v5.0)

Date of preparation: July 2025

Third-party disclaimer

You are now leaving the www.dupixentmyway.co.uk website

By clicking on “Continue” below, you will be leaving this Sanofi-hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.

Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third-party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content may be put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.


By clicking on the "Continue" button below you acknowledge that you have read this notice.